TY - JOUR
T1 - The ERA Registry Annual Report 2019
T2 - Summary and age comparisons
AU - Boenink, Rianne
AU - Astley, Megan E.
AU - Huijben, Jilske A.
AU - Stel, Vianda S.
AU - Kerschbaum, Julia
AU - Ots-Rosenberg, Mai
AU - Åsberg, Anders A.
AU - Lopot, Frantisek
AU - Golan, Eliezer
AU - Castro de la Nuez, Pablo
AU - Rodríguez Camblor, Marta
AU - Trujillo-Alemán, Sara
AU - Ruiz San Millan, Juan Carlos
AU - Ucio Mingo, Pablo
AU - Díaz, Juan Manuel
AU - Bouzas-Caamaño, M. Encarnación
AU - Artamendi, Marta
AU - Aparicio Madre, Manuel I.
AU - Santiuste de Pablos, Carmen
AU - Slon Roblero, María Fernanda
AU - Zurriaga, Oscar
AU - Stendahl, Maria E.
AU - Bell, Samira
AU - Idrizi, Alma
AU - Ioannou, Kyriakos
AU - Debska-Slizien, Alicja
AU - Galvão, Ana A.
AU - de Meester, Johan M.
AU - Resić, Halima
AU - Hommel, Kristine
AU - Radunovic, Danilo
AU - Pálsson, Runolfur
AU - Lassalle, Mathilde
AU - Finne, Patrik
AU - de Los Ángeles-Garcia Bazaga, María
AU - Gjorgjievski, Nikola
AU - Seyahi, Nurhan
AU - Bonthuis, Marjolein
AU - Ortiz, Alberto
AU - Jager, Kitty J.
AU - Kramer, Anneke
N1 - Funding Information: The ERA Registry is funded by the ERA. This article was written by R. Boenink et al. on behalf of the ERA Registry, which is an official body of the ERA. In addition, S.B. reports personal fees from AstraZeneca, outside the submitted work; A.D.-S. reports personal fees from Astellas and Fresenius, outside the submittedwork; F.L. reports personal fees fromMeditesPharma, outside the submitted work; R.P. reports grants from The Iceland Centre for Research, Landspitali University Hospital Research Fund and University of Iceland Research Fund, outside the submitted work; P.F. reports grants fromFinska läkaresällskapet and Liv och Hälsa, outside the submittedwork; M.F.S.R. reports personal fees from Baxter and Fresenius, outside the submitted work; A.O. reports grants from Sanofi, and personal fees from Astellas, AstraZeneca, Amicus, Bayes, Fresenius Medical Care and Idorsia, outside the submitted work; and K.J.J. reports grants from ERA, during the conduct of the study. Publisher Copyright: © 2021 The Author(s).
PY - 2022/3/1
Y1 - 2022/3/1
N2 - BACKGROUND: Data on renal replacement therapy (RRT) for end-stage renal disease were collected by the European Renal Association (ERA) Registry via national and regional renal registries in Europe and countries bordering the Mediterranean Sea. This article provides a summary of the 2019 ERA Registry Annual Report, including data from 34 countries and additional age comparisons.METHODS: Individual patient data for 2019 were provided by 35 registries and aggregated data by 17 registries. Using these data, the incidence and prevalence of RRT, the kidney transplantation activity and the survival probabilities were calculated.RESULTS: In 2019, a general population of 680.8 million people was covered by the ERA Registry. Overall, the incidence of RRT was 132 per million population (p.m.p.). Of these patients, 62% were men, 54% were ≥65 years of age and 21% had diabetes mellitus as primary renal disease (PRD), and 84% had haemodialysis (HD), 11% had peritoneal dialysis (PD) and 5% had pre-emptive kidney transplantation as an initial treatment modality. The overall prevalence of RRT on 31 December 2019 was 893 p.m.p., with 58% of patients on HD, 5% on PD and 37% living with a kidney transplant. The overall kidney transplant rate was 35 p.m.p. and 29% of the kidney grafts were from a living donor. The unadjusted 5-year survival probability was 42.3% for patients commencing dialysis, 86.6% for recipients of deceased donor grafts and 94.4% for recipients of living donor grafts in the period 2010-14. When comparing age categories, there were substantial differences in the distribution of PRD, treatment modality and kidney donor type, and in the survival probabilities.
AB - BACKGROUND: Data on renal replacement therapy (RRT) for end-stage renal disease were collected by the European Renal Association (ERA) Registry via national and regional renal registries in Europe and countries bordering the Mediterranean Sea. This article provides a summary of the 2019 ERA Registry Annual Report, including data from 34 countries and additional age comparisons.METHODS: Individual patient data for 2019 were provided by 35 registries and aggregated data by 17 registries. Using these data, the incidence and prevalence of RRT, the kidney transplantation activity and the survival probabilities were calculated.RESULTS: In 2019, a general population of 680.8 million people was covered by the ERA Registry. Overall, the incidence of RRT was 132 per million population (p.m.p.). Of these patients, 62% were men, 54% were ≥65 years of age and 21% had diabetes mellitus as primary renal disease (PRD), and 84% had haemodialysis (HD), 11% had peritoneal dialysis (PD) and 5% had pre-emptive kidney transplantation as an initial treatment modality. The overall prevalence of RRT on 31 December 2019 was 893 p.m.p., with 58% of patients on HD, 5% on PD and 37% living with a kidney transplant. The overall kidney transplant rate was 35 p.m.p. and 29% of the kidney grafts were from a living donor. The unadjusted 5-year survival probability was 42.3% for patients commencing dialysis, 86.6% for recipients of deceased donor grafts and 94.4% for recipients of living donor grafts in the period 2010-14. When comparing age categories, there were substantial differences in the distribution of PRD, treatment modality and kidney donor type, and in the survival probabilities.
KW - ESRD
KW - dialysis
KW - epidemiology
KW - graft survival
KW - kidney transplantation
KW - patient survival
UR - http://www.scopus.com/inward/record.url?scp=85142603970&partnerID=8YFLogxK
U2 - https://doi.org/10.1093/ckj/sfab273
DO - https://doi.org/10.1093/ckj/sfab273
M3 - Article
C2 - 35211303
SN - 2048-8505
VL - 15
SP - 452
EP - 472
JO - Clinical Kidney Journal
JF - Clinical Kidney Journal
IS - 3
ER -